Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients

Haemophilia

Volumn 17, Issue 2, 2011, Pages 275-281

  Gouw, S C ^a,b   Van Der Bom, J G ^c   Van Den Berg, H M ^b,d   Zewald, R A ^a   Ploos Van Amstel, J K ^a   Mauser Bunschoten, E P ^e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MEANDER MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Factor VIII; Genotype; Haemophilia A; Inhibitors; Mutation; Risk factors

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHILD; COHORT ANALYSIS; DISEASE SEVERITY; GENE DELETION; GENE INSERTION; GENE LOCATION; HEMOPHILIA A; HUMAN; INFANT; INTRON; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NONSENSE MUTATION; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FACTOR VIII; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEMOPHILIA A; HUMANS; INFANT; MIDDLE AGED; MUTATION; PHENOTYPE; RISK FACTORS; YOUNG ADULT;

EID: 79951793313     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02420.x     Document Type: Article

References (33)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
2. Frommel D, Allain JP. Genetic predisposition to develop factor VIII antibody in classic hemophilia. Clin Immunol Immunopathol 1977; 8: 34-8.
3. Shapiro SS. Genetic predisposition to inhibitor formation. Prog Clin Biol Res 1984; 150: 45-5.
4. Gill JC. The role of genetics in inhibitor formation. Thromb Haemost 1999; 82: 500-4.
5. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
6. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984; 150: 19-29.
7. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
8. Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
9. Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003; 29: 23-30.
10. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica 2000; 85: 7-13.
11. Tuddenham EG, McVey JH. The genetic basis of inhibitor development in haemophilia A. Haemophilia 1998; 4: 543-5.
12. Rosendaal FR, Nieuwenhuis HK, van den Berg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands Dutch Hemophilia Study Group. Blood 1993; 81: 2180-6.
13. White GC, Rosendaal F, Aledort LM et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
14. Kasper CK, Aledort L, Aronson D et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
15. Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
16. Lee ML, Gomperts ED, Kingdon HS. A note on the calculation of recovery for factor VIII infusions. Thromb Haemost 1993; 69: 87.
17. Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 1993; 5: 236-41.
18. Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood 2002; 99: 168-74.
19. Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: identification of 14 novel mutations. Thromb Haemost 2001; 85: 580-3.
20. Goodeve AC, Williams I, Bray GL, Peake IR. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate) Recombinate PUP Study Group. Thromb Haemost 2000; 83: 844-8.
21. Astermark J, Oldenburg J, Escobar M, White GC, Berntorp E. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005; 90: 924-31.
22. Vinciguerra C, Zawadzki C, Dargaud Y et al. Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France description of 62 novel mutations. Thromb Haemost 2006; 95: 593-9.
23. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
24. Green PM, Bagnall RD, Waseem NH, Giannelli F. Haemophilia A mutations in the UK: results of screening one-third of the population. Br J Haematol 2008; 143: 115-28.
25. Margaglione M, Castaman G, Morfini M et al. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica 2008; 93: 722-8.
26. Boekhorst J, Lari GR, D'Óiron R et al. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia 2008; 14: 729-35.
27. Reipert BM, van Helden PM, Schwarz HP, Hausl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol 2007; 136: 12-25.
28. Young M, Inaba H, Hoyer LW et al. Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene. Am J Hum Genet 1997; 60: 565-73.
29. Oldenburg J, Schroder J, Schmitt C, Brackmann HH, Schwaab R. Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype. Thromb Haemost 1998; 79: 452-3.
30. Oldenburg J, Albert T, Schröder J et al. Classification of factor VIII gene mutations according to risk of inhibitor formation. Haemophilia 2008; 14(Suppl. 2): 1-120. Abstract 09FP05.
31. David D, Santos IM, Johnson K, Tuddenham EG, McVey JH. Analysis of the consequences of premature termination codons within factor VIII coding sequences. J Thromb Haemost 2003; 1: 139-46.
32. Levinson B, Kenwrick S, Gamel P, Fisher K, Gitschier J. Evidence for a third transcript from the human factor VIII gene. Genomics 1992; 14: 585-9.
33. Stalder L, Muhlemann O. The meaning of nonsense. Trends Cell Biol 2008; 18: 315-21.